Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Standard Chartered Head of Digital Asset Research: Bitcoin Bottom "Is Near", Maintains $100,000 Year-End Target

Standard Chartered Head of Digital Asset Research: Bitcoin Bottom "Is Near", Maintains $100,000 Year-End Target

ChaincatcherChaincatcher2026/06/04 10:34
Show original

ChainCatcher reports, citing The Block, that Geoffrey Kendrick, Head of Digital Assets Research at Standard Chartered Bank, stated that after the recent sharp drop, Bitcoin has "almost bottomed," and the current range around $63,000 is a "buy zone." He pointed out that since February, U.S. spot Bitcoin ETF holdings have remained basically flat overall, with no feared mass redemptions, indicating that capital is now "structurally more stable."

Kendrick expects that after the recent selling pressure caused by Strategy selling 32 BTC, there may be a buyback of 10 times or even 100 times the scale, following historical patterns, which could signal confirmation of a short-term low. He also warned that Bitcoin still faces downside risk of falling below $60,000, but argued that buying in batches is better than trying to time the exact bottom. The bank maintains its year-end targets for Bitcoin at $100,000 and Ethereum at $4,000.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage